149 related articles for article (PubMed ID: 31409568)
1. Radiofrequency Ablation Duration per Tumor Volume May Correlate with Overall Survival in Solitary Hepatocellular Carcinoma Patients Treated with Radiofrequency Ablation Plus Lyso-Thermosensitive Liposomal Doxorubicin.
Celik H; Wakim P; Pritchard WF; Castro M; Leonard S; Karanian JW; Dewhirst MW; Lencioni R; Wood BJ
J Vasc Interv Radiol; 2019 Dec; 30(12):1908-1914. PubMed ID: 31409568
[TBL] [Abstract][Full Text] [Related]
2. Phase III HEAT Study Adding Lyso-Thermosensitive Liposomal Doxorubicin to Radiofrequency Ablation in Patients with Unresectable Hepatocellular Carcinoma Lesions.
Tak WY; Lin SM; Wang Y; Zheng J; Vecchione A; Park SY; Chen MH; Wong S; Xu R; Peng CY; Chiou YY; Huang GT; Cai J; Abdullah BJJ; Lee JS; Lee JY; Choi JY; Gopez-Cervantes J; Sherman M; Finn RS; Omata M; O'Neal M; Makris L; Borys N; Poon R; Lencioni R
Clin Cancer Res; 2018 Jan; 24(1):73-83. PubMed ID: 29018051
[No Abstract] [Full Text] [Related]
3. Thermosensitive liposomal doxorubicin plus radiofrequency ablation increased tumor destruction and improved survival in patients with medium and large hepatocellular carcinoma: A randomized, double-blinded, dummy-controlled clinical trial in a single center.
Yang W; Lee JC; Chen MH; Zhang ZY; Bai XM; Yin SS; Cao K; Wang S; Wu W; Yan K
J Cancer Res Ther; 2019; 15(4):773-783. PubMed ID: 31436231
[TBL] [Abstract][Full Text] [Related]
4. Transarterial Chemoembolization Followed by Radiofrequency Ablation for Hepatocellular Carcinoma: Impact of the Time Interval between the Two Treatments on Outcome.
Liu D; Liu M; Su L; Wang Y; Zhang X; Long H; Kuang M; Xie X; Lin M
J Vasc Interv Radiol; 2019 Dec; 30(12):1879-1886. PubMed ID: 31669087
[TBL] [Abstract][Full Text] [Related]
5. Imaging Features of Radiofrequency Ablation with Heat-Deployed Liposomal Doxorubicin in Hepatic Tumors.
Hong CW; Chow L; Turkbey EB; Lencioni R; Libutti SK; Wood BJ
Cardiovasc Intervent Radiol; 2016 Mar; 39(3):409-16. PubMed ID: 26228246
[TBL] [Abstract][Full Text] [Related]
6. Lyso-thermosensitive liposomal doxorubicin: an adjuvant to increase the cure rate of radiofrequency ablation in liver cancer.
Poon RT; Borys N
Future Oncol; 2011 Aug; 7(8):937-45. PubMed ID: 21823888
[TBL] [Abstract][Full Text] [Related]
7. Chemoembolization Combined with Radiofrequency Ablation for Medium-Sized Hepatocellular Carcinoma: A Propensity-Score Analysis.
Chu HH; Kim JH; Yoon HK; Ko HK; Gwon DI; Kim PN; Sung KB; Ko GY; Kim SY; Park SH
J Vasc Interv Radiol; 2019 Oct; 30(10):1533-1543. PubMed ID: 31471190
[TBL] [Abstract][Full Text] [Related]
8. Locoregional Therapy of Hepatocellular-Cholangiocarcinoma versus Hepatocellular Carcinoma: A Propensity Score-Matched Study.
Huang YH; Park BV; Chen YF; Gaba RC; Guzman G; Lokken RP
J Vasc Interv Radiol; 2019 Sep; 30(9):1317-1324. PubMed ID: 31375450
[TBL] [Abstract][Full Text] [Related]
9. Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer.
Poon RT; Borys N
Expert Opin Pharmacother; 2009 Feb; 10(2):333-43. PubMed ID: 19236203
[TBL] [Abstract][Full Text] [Related]
10. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
[TBL] [Abstract][Full Text] [Related]
11. Conventional Chemoembolization Plus Radiofrequency Ablation versus Surgical Resection for Single, Medium-Sized Hepatocellular Carcinoma: Propensity-Score Matching Analysis.
Lee HJ; Kim JW; Hur YH; Cho SB; Lee BC; Lee BK; Hwang EC; Cho YS; Seon HJ
J Vasc Interv Radiol; 2019 Mar; 30(3):284-292.e1. PubMed ID: 30819467
[TBL] [Abstract][Full Text] [Related]
12. Combined Therapy with Transarterial Chemoembolization and Radiofrequency Ablation for Hepatocellular Carcinoma: Does the Degree of Ethiodized Oil Accumulation within the Tumor Affect the Therapeutic Efficacy?
Lee JE; Kim JW; Kim HO; Lee BC; Hur YH; Cho SB; Cho YS; Seon HJ; Kim D
J Vasc Interv Radiol; 2019 Mar; 30(3):370-379.e4. PubMed ID: 30819479
[TBL] [Abstract][Full Text] [Related]
13. Management of people with early- or very early-stage hepatocellular carcinoma: an attempted network meta-analysis.
Majumdar A; Roccarina D; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011650. PubMed ID: 28351116
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of heat-deployed liposomal doxorubicin during radiofrequency ablation for hepatic malignancies.
Wood BJ; Poon RT; Locklin JK; Dreher MR; Ng KK; Eugeni M; Seidel G; Dromi S; Neeman Z; Kolf M; Black CD; Prabhakar R; Libutti SK
J Vasc Interv Radiol; 2012 Feb; 23(2):248-55.e7. PubMed ID: 22178041
[TBL] [Abstract][Full Text] [Related]
15. Chemoradionuclide therapy with 186Re-labeled liposomal doxorubicin in combination with radiofrequency ablation for effective treatment of head and neck cancer in a nude rat tumor xenograft model.
Soundararajan A; Dodd GD; Bao A; Phillips WT; McManus LM; Prihoda TJ; Goins BA
Radiology; 2011 Dec; 261(3):813-23. PubMed ID: 22025735
[TBL] [Abstract][Full Text] [Related]
16. Transarterial Chemoembolization versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma after Resection within Barcelona Clinic Liver Cancer Stage 0/A: A Retrospective Comparative Study.
Chen R; Gan Y; Ge N; Chen Y; Wang Y; Zhang B; Wang Y; Ye S; Ren Z
J Vasc Interv Radiol; 2016 Dec; 27(12):1829-1836. PubMed ID: 27553917
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin-eluting bead-enhanced radiofrequency ablation of hepatocellular carcinoma: a pilot clinical study.
Lencioni R; Crocetti L; Petruzzi P; Vignali C; Bozzi E; Della Pina C; Bargellini I; Cioni D; Oliveri F; De Simone P; Bartolozzi C; Brunetto M; Filipponi F
J Hepatol; 2008 Aug; 49(2):217-22. PubMed ID: 18486261
[TBL] [Abstract][Full Text] [Related]
18. RFA plus lyso-thermosensitive liposomal doxorubicin: in search of the optimal approach to cure intermediate-size hepatocellular carcinoma.
Lencioni R; Cioni D
Hepat Oncol; 2016 Aug; 3(3):193-200. PubMed ID: 30191041
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant liposomal doxorubicin markedly affects radiofrequency ablation-induced effects on periablational microvasculature.
Moussa M; Goldberg SN; Tasawwar B; Sawant RR; Levchenko T; Kumar G; Torchilin VP; Ahmed M
J Vasc Interv Radiol; 2013 Jul; 24(7):1021-33. PubMed ID: 23664809
[TBL] [Abstract][Full Text] [Related]
20. Microwave versus Radiofrequency Ablation Treatment for Hepatocellular Carcinoma: A Comparison of Efficacy at a Single Center.
Potretzke TA; Ziemlewicz TJ; Hinshaw JL; Lubner MG; Wells SA; Brace CL; Agarwal P; Lee FT
J Vasc Interv Radiol; 2016 May; 27(5):631-8. PubMed ID: 27017124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
